Tempus AI (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.

Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.

The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.

Tempus AI shares were up nearly 2% in recent premarket activity.